Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006040668> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2006040668 endingPage "737" @default.
- W2006040668 startingPage "733" @default.
- W2006040668 abstract "What is already known about this subject • The initial indication for endothelin (ET) receptor antagonism as a treatment strategy, primary pulmonary hypertension, is now expanding to include scleroderma, which can cause both pulmonary and renal disease. • It is important to understand the effects of impaired renal function on the pharmacokinetics of these drugs to allow appropriate dosing in individuals with impaired renal function. What this study adds • Sitaxsentan, an oral selective endothelin A receptor antagonist, is licensed for the treatment of pulmonary hypertension, and studies of this drug in CKD are planned. • The pharmacokinetic profile of sitaxsentan is unchanged in subjects with varying degrees of renal impairment. • The results of this study will allow confident dosing of sitaxsentan in individuals with renal impairment, and inform future studies. Aim To investigate the pharmacokinetic profile of a single 100‐mg oral dose of sitaxsentan, a selective endothelin type A receptor antagonist, in subjects with normal and impaired renal function. Methods This was an open label, single oral dose study in subjects with normal [creatinine clearance (CrCL) ≥ 80 ml min −1 ] and impaired renal function (mild renal impairment CrCL 51–80 ml min −1 , moderate impairment CrCL 31–50 ml min −1 , severe impairment CrCL ≤ 30 ml min −1 ). All subjects received a dose of 100 mg sitaxsentan. Results Twenty‐four subjects were enrolled, six in each of the normal and three renal impairment groups. The mean plasma sitaxsentan concentrations were comparable across the groups, as were the mean values for C max (10.3–13.9 µg ml −1 ), AUC ∞ (18.7–22.5 h µg −1 ml −1 ), oral clearance (CL/F, 82.3–94.9 ml min −1 ), volume of distribution ( V z/F, 64.8–69.6 l) and elimination half‐life ( t 1/2 , 8.6–9.6 h). There was substantial overlap among the four groups in the individual subject values for CL/F and V z/F and no relationship between either of these parameters and CrCL. Conclusion After a single 100‐mg oral dose of sitaxsentan there were no differences in its pharmacokinetics among subjects with normal or impaired renal function." @default.
- W2006040668 created "2016-06-24" @default.
- W2006040668 creator A5000572967 @default.
- W2006040668 creator A5046696016 @default.
- W2006040668 creator A5060132287 @default.
- W2006040668 creator A5060410193 @default.
- W2006040668 creator A5075818401 @default.
- W2006040668 creator A5081449769 @default.
- W2006040668 creator A5085998748 @default.
- W2006040668 creator A5046897692 @default.
- W2006040668 date "2007-07-17" @default.
- W2006040668 modified "2023-10-18" @default.
- W2006040668 title "The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment" @default.
- W2006040668 cites W1550111394 @default.
- W2006040668 cites W1955970211 @default.
- W2006040668 cites W1977343715 @default.
- W2006040668 cites W2021160040 @default.
- W2006040668 cites W2023453199 @default.
- W2006040668 cites W2024322045 @default.
- W2006040668 cites W2076644187 @default.
- W2006040668 cites W2115537569 @default.
- W2006040668 cites W2159819952 @default.
- W2006040668 cites W2163370089 @default.
- W2006040668 cites W2298101895 @default.
- W2006040668 doi "https://doi.org/10.1111/j.1365-2125.2007.02979.x" @default.
- W2006040668 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2198787" @default.
- W2006040668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17635499" @default.
- W2006040668 hasPublicationYear "2007" @default.
- W2006040668 type Work @default.
- W2006040668 sameAs 2006040668 @default.
- W2006040668 citedByCount "7" @default.
- W2006040668 countsByYear W20060406682019 @default.
- W2006040668 countsByYear W20060406682020 @default.
- W2006040668 crossrefType "journal-article" @default.
- W2006040668 hasAuthorship W2006040668A5000572967 @default.
- W2006040668 hasAuthorship W2006040668A5046696016 @default.
- W2006040668 hasAuthorship W2006040668A5046897692 @default.
- W2006040668 hasAuthorship W2006040668A5060132287 @default.
- W2006040668 hasAuthorship W2006040668A5060410193 @default.
- W2006040668 hasAuthorship W2006040668A5075818401 @default.
- W2006040668 hasAuthorship W2006040668A5081449769 @default.
- W2006040668 hasAuthorship W2006040668A5085998748 @default.
- W2006040668 hasBestOaLocation W20060406682 @default.
- W2006040668 hasConcept C112705442 @default.
- W2006040668 hasConcept C126322002 @default.
- W2006040668 hasConcept C126894567 @default.
- W2006040668 hasConcept C144980905 @default.
- W2006040668 hasConcept C159641895 @default.
- W2006040668 hasConcept C170493617 @default.
- W2006040668 hasConcept C2776345702 @default.
- W2006040668 hasConcept C2776885963 @default.
- W2006040668 hasConcept C2777056448 @default.
- W2006040668 hasConcept C2777288759 @default.
- W2006040668 hasConcept C2778653478 @default.
- W2006040668 hasConcept C2780306776 @default.
- W2006040668 hasConcept C2908822073 @default.
- W2006040668 hasConcept C71924100 @default.
- W2006040668 hasConcept C98274493 @default.
- W2006040668 hasConceptScore W2006040668C112705442 @default.
- W2006040668 hasConceptScore W2006040668C126322002 @default.
- W2006040668 hasConceptScore W2006040668C126894567 @default.
- W2006040668 hasConceptScore W2006040668C144980905 @default.
- W2006040668 hasConceptScore W2006040668C159641895 @default.
- W2006040668 hasConceptScore W2006040668C170493617 @default.
- W2006040668 hasConceptScore W2006040668C2776345702 @default.
- W2006040668 hasConceptScore W2006040668C2776885963 @default.
- W2006040668 hasConceptScore W2006040668C2777056448 @default.
- W2006040668 hasConceptScore W2006040668C2777288759 @default.
- W2006040668 hasConceptScore W2006040668C2778653478 @default.
- W2006040668 hasConceptScore W2006040668C2780306776 @default.
- W2006040668 hasConceptScore W2006040668C2908822073 @default.
- W2006040668 hasConceptScore W2006040668C71924100 @default.
- W2006040668 hasConceptScore W2006040668C98274493 @default.
- W2006040668 hasIssue "6" @default.
- W2006040668 hasLocation W20060406681 @default.
- W2006040668 hasLocation W20060406682 @default.
- W2006040668 hasLocation W20060406683 @default.
- W2006040668 hasLocation W20060406684 @default.
- W2006040668 hasOpenAccess W2006040668 @default.
- W2006040668 hasPrimaryLocation W20060406681 @default.
- W2006040668 hasRelatedWork W1592707747 @default.
- W2006040668 hasRelatedWork W1979626596 @default.
- W2006040668 hasRelatedWork W1986060795 @default.
- W2006040668 hasRelatedWork W2040354764 @default.
- W2006040668 hasRelatedWork W2051831228 @default.
- W2006040668 hasRelatedWork W2116152202 @default.
- W2006040668 hasRelatedWork W2369362743 @default.
- W2006040668 hasRelatedWork W2381977691 @default.
- W2006040668 hasRelatedWork W2418287413 @default.
- W2006040668 hasRelatedWork W2898845055 @default.
- W2006040668 hasVolume "64" @default.
- W2006040668 isParatext "false" @default.
- W2006040668 isRetracted "false" @default.
- W2006040668 magId "2006040668" @default.
- W2006040668 workType "article" @default.